Figure 1. Dyslipidemia (Dyslipoproteinemia) Recommendations Summary
Assess both 10 year CHD and Lifetime Risk using tables (pages 7, 9, 20-21)
Step 1:
Establish Goals of Therapy (page 11)
Step 2:
Laboratory Evaluation (page 11)
Step 3:
• Fasting lipid profile • LDL particle number • Thyroid stimulating hormone
• Fasting glucose High Risk
Moderate Risk Low Risk
Table 2 (page 9)
Table 3-4 (page 10)
• HbA1c • Blood urea nitrogen • Creatinine • Urinalysis • Liver function tests
Additional Biomarker Considerations • Assessment of insulin resistance ▶ Lipoprotein insulin resistance score ▶ Insulin level (HOMA Score)
• Lp(a) • Inflammatory markers: ▶ hs-CRP ▶ Lp-PLA2 ▶ Myeloperoxidase
• Vitamin D3 • Homocysteine
Clinical Intervention (pages 12-18)
Step 4:
Assess Response to Therapy
Step 5: (page 13) (pages 13-18) Tables 5-7
Repeat lipid and LDL particle number tests every 3 months until goals are reached, then annually or semi-annually thereafter
CHD, coronary heart disease; HbA1c, glycosylated hemoglobin A1c; hs-CRP, high-sensitivity , lipoprotein-associated phospholipase A2
c-reactive protein; LDL, low-density lipoprotein; LDL-P, low-density lipoprotein particle number; Lp(a), lipoprotein (a); Lp-PLA2
1
